variant of concern

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin

This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection. Click …

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin Read More »

TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin

This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals. Click arrow to playDownload TWiV 831 (20 MB .mp3, …

TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin Read More »

TWiV 830: A culture of resistance

This Week in Virology / By Vincent Racaniello

TWiV explains that a recent report suggesting that the SARS-CoV-2 spike protein inhibits V(D)J recombination in vitrowould not impact immunity after infection or vaccination, and describes the isolation of remdesivir resistant mutants in cells in culture, and the emergence of amino acid changes in the spike protein identical to those in variants of concern, in the …

TWiV 830: A culture of resistance Read More »

TWiV 828: COVID-19 clinical update #88 with Dr. Daniel Griffin

This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death. Show notes at microbe.tv/twiv

Estimate of infectiousness during COVID-19

5 Comments / Basic virology / By Vincent Racaniello

Understanding the transmission of SARS-CoV-2 is complicated by the large numbers of presymptomatic, asymptomatic, and mildly symptomatic (PAMS) patients. The reproductive number, R0, is a measure of population-level dynamics, but it cannot provide information on infectiousness of different groups such as PAMS subjects; when peak infectiousness occurs; and the effect of intrinsic properties of the …

Estimate of infectiousness during COVID-19 Read More »

SARS-CoV-2 variant B.1.1.7 is not more virulent

9 Comments / Basic virology, Commentary / By Vincent Racaniello

When the B.1.1.7 variant of SARS-CoV-2 was first detected in the UK in December 2020 it was accompanied by unsubstantiated claims of increased transmissibility and virulence. The results of a hospital-based study in London reveals no association of the variant with severe disease in this cohort. In a note published by NERVTAG on 21 January …

SARS-CoV-2 variant B.1.1.7 is not more virulent Read More »

Start typing and press enter to search